SoftOx Solutions AS (SoftOx) announces that it has published its Annual Report
for 2024. The Board of Directors has approved the 2024 annual financial
statements prepared in accordance with the Norwegian Accounting Act and
accounting standards and practices generally accepted in Norway. The documents
are also available at the Company's website, https://soft-ox.com 


For further information, please contact: 

Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87 

Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165 

Mail: ir@soft-ox.com  
 

About SoftOx Solutions AS: 

SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
listed on Euronext Growth Oslo. The company is developing highly effective
pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The
technology is based on extensive research and development in partnership with
leading Nordic research institutes.